Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Myelodysplastic Syndromes 2Mycosis Fungoides 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Myeloid, Acute 2Urinary Bladder Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell 1Immunoblastic Lymphadenopathy 1Gliosarcoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Temozolomide 5Radiotherapy 3Radiation 2veliparib 1peposertib 1Photons 1Mycophenolic Acid 1Magnetic Resonance Spectroscopy 1Lomustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × Photons × 30 days × Clear all
NCT05095376 2026-05-19

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NRG Oncology

Phase 3 Active not recruiting
265 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡